Larimar Therapeutics, Inc. (LRMR) Misses Q1 EPS by 3c

Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q1 EPS of ($0.27), $0.03 worse than the analyst estimate of ($0.24).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating
• Robinhood prices $2B convertible notes offering due 2029